Loading
CodeBreaK 100 gave the first KRAS inhibitor to 38 people whose pancreatic cancer carried the rare G12C mutation and had progressed after chemotherapy; one in five tumours shrank and patients lived a median 6.9 months, proof that KRAS can be drugged in this disease even though the target is uncommon here.
The pooled phase 1 and 2 pancreatic cohort of CodeBreaK 100 treated 38 patients, all metastatic and previously treated (median two prior lines, range one to eight). Eight had a centrally confirmed objective response (21 percent, 95 percent confidence interval 10 to 37); median progression-free survival was 4.0 months (2.8 to 5.6) and median overall survival 6.9 months (5.0 to 9.1). Treatment-related adverse events occurred in 16 patients (42 percent), grade 3 in six (16 percent), with no fatal events or discontinuations. Sotorasib has no pancreatic indication from the FDA (label: KRAS G12C lung cancer and, with panitumumab, colorectal cancer) or the EMA, and NICE's TA781 covers lung cancer only; NCCN lists sotorasib and adagrasib (KRYSTAL-1: 7 of 21 responses) as options for KRAS G12C pancreatic cancer after first-line therapy, and daraxonrasib, which covers G12C among all RAS G12 mutations, is now approved in the United States for previously treated metastatic disease regardless of subtype.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
38 treated.
8 of 38; 95% CI 10 to 37
SourceShares RASolute 302, KRAS mutation subtypes (G12C, G12D, G12V), KRAS & RAS inhibitors, KRAS.
Shares KRAS mutation subtypes (G12C, G12D, G12V), Sotorasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
Shares RASolute 302, KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib, KRAS & RAS inhibitors.
Shares Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib, KRAS & RAS inhibitors, Metastatic pancreatic ductal adenocarcinoma.
Shares Sotorasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors, KRAS.
Shares RASolute 302, Daraxonrasib, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS & RAS inhibitors.
Shares KRAS mutation subtypes (G12C, G12D, G12V), Daraxonrasib, KRAS & RAS inhibitors, Metastatic pancreatic ductal adenocarcinoma.